AGK-BRAF fusion
|
Melanoma
|
AGK-BRAF fusion
|
Melanoma
|
sorafenib Sensitive: D – Preclinical
|
sorafenib Sensitive: D – Preclinical
|
AGK-BRAF fusion
|
Melanoma
|
AGK-BRAF fusion
|
Melanoma
|
PLX8394 Resistant: D – Preclinical
|
PLX8394 Resistant: D – Preclinical
|
AGK-BRAF fusion
|
Melanoma
|
AGK-BRAF fusion
|
Melanoma
|
dabrafenib Resistant: D – Preclinical
|
dabrafenib Resistant: D – Preclinical
|
AGK-BRAF fusion
|
Melanoma
|
AGK-BRAF fusion
|
Melanoma
|
vemurafenib Resistant: D – Preclinical
|
vemurafenib Resistant: D – Preclinical
|